Name | Piperlongumine |
---|---|
Synonyms |
Piperlongumine
1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]- (E)-Piplartine 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone piplartine 1-[3-(3,4,5-Trimethoxy-phenyl)-acryloyl]-5,6-dihydro-1H-pyridin-2-one 2(1H)-Pyridinone, 5,6-dihydro-1-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, (E)- 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)prop-2-enoyl]-5,6-dihydropyridin-2(1H)-one |
Description | Piperlongumine is a natural alkaloid isolated from Piper longum Linn[1], possesses ant-inflammatory, antibacterial, antiangiogenic, antioxidant, antitumor, and antidiabetic activities[2]. Piperlongumine induces ROS, and induces apoptosis in cancer cell lines[1]. Piperlongumine shows anti-cardiac fibrosis activity, suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway[2]. |
---|---|
Related Catalog | |
Target |
ERK1 ERK2 |
In Vitro | Piplartine (5, 10, and 15 μM) significantly decreases cell proliferation of 786-O, SKBR3, Panc1, A549, and L3.6pL cancer cells after treatment for 24 and 48 hours, induces apoptosis and ROS in these cell lines at 5 and 10 μM after 3 or 9 h of treatment[1]. Piplartine (5 or 10 μM) induces cleaved PARP and downregulates Sp1, Sp3, Sp4, and Sp-regulated genes[1]. Piplartine (20 μM) decreases the viability of cardiac fibroblasts (CFs). Piplartine (0-10 μM) suppresses myofibroblast transformation via suppression of the ERK1/2 signaling pathway[2]. |
In Vivo | Piperlongumine (30 mg/kg/day, i.p. for 3 weeks) exhibits potent anti-tumor effect in athymic nude mice bearing L3.6pL cells without body weight loss[1]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 475.6±45.0 °C at 760 mmHg |
Melting Point | 124ºC |
Molecular Formula | C17H19NO5 |
Molecular Weight | 317.336 |
Flash Point | 241.4±28.7 °C |
Exact Mass | 317.126312 |
PSA | 65.07000 |
LogP | 2.34 |
Appearance | white to beige |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.581 |
Storage condition | 2-8°C |
Water Solubility | DMSO: ≥5mg/mL at warmed to 60°C |
RIDADR | NONH for all modes of transport |
---|---|
WGK Germany | 3 |
RTECS | UU7785850 |
HS Code | 2933399090 |
~42% 20069-09-4 |
Literature: Boll, Per M.; Hansen, Jesper; Simonsen, Ole; Thorup, Niels Tetrahedron, 1984 , vol. 40, # 1 p. 171 - 176 |
~% 20069-09-4 |
Literature: Tetrahedron, , vol. 40, # 1 p. 171 - 176 |
~% 20069-09-4 |
Literature: European Journal of Medicinal Chemistry, , vol. 57, p. 344 - 361 |
~% 20069-09-4 |
Literature: European Journal of Medicinal Chemistry, , vol. 57, p. 344 - 361 |
~% 20069-09-4 |
Literature: European Journal of Medicinal Chemistry, , vol. 57, p. 344 - 361 |
~% 20069-09-4 |
Literature: European Journal of Medicinal Chemistry, , vol. 57, p. 344 - 361 |
HS Code | 2933399090 |
---|---|
Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |